Viridian Therapeutics Says REVEAL-1 Study Met Primary Endpoint Of Every Four Weeks (Q4W) Proptosis Responder Rate In Thyroid Eye Disease

Viridian Therapeutics announced that its REVEAL-1 study met the primary endpoint of the Q4W proptosis responder rate (PRR) with a significant treatment effect, showing 54% and 63% PRR for elegrobart Q4W and Q8W respectively, compared to 18% for placebo at week 24. Additionally, 51% of patients treated with elegrobart Q4W experienced complete resolution of diplopia versus 16% for placebo. The company ended Q4 2025 with $875 million in cash and expects to fund its business plans through profitability with potential revenue from upcoming product approvals. The REVEAL-2 trial is set for topline readout in Q2 2026, with a BLA submission anticipated in Q1 2027.